Both Biofrontera AG (NASDAQ:BFRA) and CorMedix Inc. (NYSEAMERICAN:CRMD) are Biotechnology companies, competing one another. We will compare their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera AG	N/A	0.00	N/A	-0.76	0.00
CorMedix Inc.	N/A	509.04	26.83M	-0.50	0.00

Table 1 highlights Biofrontera AG and CorMedix Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows Biofrontera AG and CorMedix Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Biofrontera AG	0.00%	0%	0%
CorMedix Inc.	0.00%	0%	-424.3%

Insider & Institutional Ownership

The shares of both Biofrontera AG and CorMedix Inc. are owned by institutional investors at 2.04% and 15.2% respectively. About 0.04% of Biofrontera AG’s share are owned by insiders. Insiders Comparatively, owned 1.7% of CorMedix Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Biofrontera AG	-4.8%	5.22%	-12.46%	-8.79%	0%	3.25%
CorMedix Inc.	-14.29%	-19.4%	20.9%	196.22%	460.55%	25.58%

For the past year Biofrontera AG was less bullish than CorMedix Inc.

Summary

CorMedix Inc. beats Biofrontera AG on 4 of the 6 factors.

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Bridgewater, New Jersey.